"10.1371_journal.pone.0089974","plos one","2014-03-20T00:00:00Z","Emily A Burger; Stephen Sy; Mari Nygård; Ivar S Kristiansen; Jane J Kim","University of Oslo, Department of Health Management and Health Economics, Oslo, Norway; Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science Boston, Massachusetts, United States of America; Cancer Registry of Norway Department of Research, Oslo, Norway","Conceived and designed the experiments: EAB MN ISK JJK. Performed the experiments: EAB SS. Analyzed the data: EAB SS JJK ISK. Wrote the paper: EAB SS MN ISK JJK.","ISK and MN are members of the Norwegian Directorate of Health National Advisory Board for cervical cancer screening. MN has received a research grant through her affiliated institution, the Cancer Registry of Norway, from MSD Norge (a subsidiary of Merck & Co) to perform registry linkage studies. Specifically, and in order to adhere to regulatory commitment, the Nordic Cancer Registries were invited by Merck & Co. Inc. to perform two analyses: 1) The long term follow-up (LTFU) study that evaluates the long-term effectiveness, safety and immunogenicity of GARDASIL (Human Papillomavirus [types 6,11,16,18] Recombinant Vaccine) over 14 years among vaccinated subjects who were enrolled in the clinical phase III study and residing in one of the four Nordic countries (Denmark, Iceland, Norway and Sweden), 2) “Vaccine Impact in Population (VIP) study for GARDASIL®” to evaluate the impact of GARDASIL (Human Papillomavirus [types 6,11,16,18] Recombinant Vaccine) in the general female population. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm111283.htm. The competing interests declared do not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","03","Emily A Burger","EAB",5,TRUE,4,2,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
